Skip to Main Content

Paper Details

Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
Cancer Res
0
2020
CXCR7, Enzalutamide, MAPK, Prostate Cancer

Datasets

Release 1.2